Approval of proposal to widen access to imiglucerase for type 1 and type 3 Gaucher disease
PHARMAC is pleased to announce the approval of a proposal to widen access to imiglucerase (Cerezyme) from 1 September 2013.
In summary, the effect of the decision is that:
- The access criteria will be widened to included funded access to imiglucerase for patients with type 3 Gaucher disease;
- The maximum funded dose of imiglucerase will be increased from 15 iu/kg per month to 30 iu/kg per month for children with type 1 or type 3 Gaucher disease meeting certain criteria.